Should all patients at high risk of atherothrombotic events receive dual antiplatelet therapy?

Nature Clinical Practice Neurology

Volumn 2, Issue 10, 2006, Pages 532-533

  Adams, Robert J ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PLACEBO;

ARTERY DISEASE; BLEEDING; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEATH; DISEASE SEVERITY; DRUG EFFICACY; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; LOW DRUG DOSE; MONOTHERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZATION; RISK FACTOR; SHORT SURVEY; STROKE; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS;

EID: 33748988453     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro0297     Document Type: Short Survey

References (5)

1. Diener HC et al. (2004) Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet 364: 331-337
2. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329-1339
3. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345: 494-502
4. Sabatine MS et al. (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352: 1179-1189
5. Smith SC Jr et al. (2006) AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation 113: 2363-2372